Coya announces an Agreement with Dr. Reddy’s to License biosimilar Abatacept
21 Mar 2023 //
BUSINESSWIRE
NIH-led Covid-19 trial shows immune modulator drugs boost survival
18 Jul 2022 //
CLINICALTRIALSARENA
BMS’ Orencia boosts survival in Phase III Covid-19 trial
03 Jun 2022 //
CLINICALTRIALSARENA
Immune modulator drugs improves survival for people hospitalised with COVID-19
03 Jun 2022 //
EXPRESS PHARMA
Bristol Myers` Biologic Orencia (Abtacept) Receives Approval in the U.S.
13 Apr 2022 //
FDA
BMS`s Orencia wins FDA nod for prevention of GVHD
16 Dec 2021 //
FIERCEPHARMA
BMS` Orencia snagged priority review in transplant rejection
24 Aug 2021 //
FIERCEPHARMA
Bristol Myers`s Orencia (Abatacept ) Receives Supplemental Approval in US
24 Jun 2020 //
FDA
Abbvie`s Rinvoq matches BMS` Orencia in head-to-head RA trial
08 Jun 2020 //
FIERCE PHARMA
AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary
07 Jun 2020 //
PRESS RELEASE
BMY`s Precision-Focused Immunology Leadership with New Data on ORENCIA®
07 Nov 2019 //
PRESS RELEASE
Momenta calls time on biosimilar R&D, cuts half its staff
03 Oct 2018 //
FIERCE BIOTECH